Founded in 2017, Hanne Capital is a healthcare specialty private equity investment fund focusing on growth opportunities in Greater China. The founding partners are all veterans with years of senior leadership experience at industry leading private equity fund or world-renowned multinationals in pharma, medtech & biotech industries. Each founding partner has achieved industry milestones in their previous career. Hanne team consists of seasoned professionals with sharp business acumen and rich experience of investments and believes strongly in high standards of ethics and professionalism. Historically the founding partners have deployed over US$330 million into a number of companies and played pivotal roles in the growth of these investees. Many of our portfolios have successfully listed on renowned stock exchanges in mainland China, US, Hong Kong and Taiwan with a collective market capitalization over US$6.2 billion. Our representative portfolios include BeiGene (NASDAQ: BGNE)，TaiGen (GTSM: 4157), Hile Bio-tech (SH: 603718)，HEC Changjiang Pharma (HK:1558)，Golden Meditech (HK: 801) and Ready Health (SH: 600090)，SinoMed, OrbiePharm and Allgens. We look for companies with great growth potential in pharma & biotech, medtech and healthcare services sectors and choose to partner with management teams with integrity and solid execution capabilities. We will work closely with our portfolios as an extended team to create value by leveraging our broad network of connections and deep domain expertise in growth strategy, business developments, cross-border IP transactions and operation improvements. http://www.hannecapital.com

New Horizon Capital is a leading mid-market private equity firm focusing on growth opportunities in a variety of industries in Greater China. Total AUM exceeded US$4 biilion by the time I left in late 2016. I was leading a team of 8 investment professionals and was in charge of its healthcare practice from 2012-2016. Achieved 6 IPOs and 3.2X DPI.

- Sourcing and executing minority equity investments in China and Asia Pacific countries (including Japan)- Execute potential acquisitions in Asia Pacific- Support corporate strategic initiatives in China and Asia Pacific